In bDMARD-naïve RA patients, abatacept showed a lower risk of cardiovascular events than TNF inhibitors in specific subgroups with a history of CVD, type 2 diabetes mellitus, and in elderly patients (age ≥ 65 years) [72,73,74]. This evidence concerns the gene TNF and type 2 diabetes mellitus.